NasdaqGS:MYGN

Stock Analysis Report

Executive Summary

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide.

Snowflake

Fundamentals

Adequate balance sheet with moderate growth potential.


Similar Companies

Share Price & News

How has Myriad Genetics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.9%

MYGN

0.8%

US Biotechs

1.0%

US Market


1 Year Return

-32.4%

MYGN

-8.3%

US Biotechs

6.7%

US Market

Return vs Industry: MYGN underperformed the US Biotechs industry which returned -8.3% over the past year.

Return vs Market: MYGN underperformed the US Market which returned 6.7% over the past year.


Share holder returns

MYGNIndustryMarket
7 Day1.9%0.8%1.0%
30 Day7.6%-3.9%-1.8%
90 Day13.5%-3.5%-1.8%
1 Year-32.4%-32.4%-7.5%-8.3%9.1%6.7%
3 Year52.8%52.8%13.6%9.6%46.1%36.6%
5 Year-15.7%-15.7%3.3%-1.7%66.9%48.6%

Price Volatility Vs. Market

How volatile is Myriad Genetics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Myriad Genetics undervalued based on future cash flows and its price relative to the stock market?

471.52x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: MYGN ($29.51) is trading above our estimate of fair value ($24.84)

Significantly Undervalued: MYGN is trading above our estimate of fair value.


Price Based on Earnings

PE vs Industry: MYGN is poor value based on its PE Ratio (471.5x) compared to the Biotechs industry average (17.2x).

PE vs Market: MYGN is poor value based on its PE Ratio (471.5x) compared to the US market (17.5x).


Price Based on Expected Growth

Low PEG Ratio: MYGN is poor value based on its PEG Ratio (5.8x)


Price Based on Value of Assets

PB vs Industry: MYGN is good value based on its PB Ratio (2x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is Myriad Genetics expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

80.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: MYGN's forecast earnings growth (80.9% per year) is above the savings rate (2.7%).

Earnings vs Market: MYGN's earnings (80.9% per year) are forecast to grow faster than the US market (14.5% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: MYGN's revenue (3.4% per year) is forecast to grow slower than the US market (7.3% per year).

High Growth Revenue: MYGN's revenue (3.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: MYGN's Return on Equity is forecast to be low in 3 years time (11.4%).


Next Steps

Past Performance

How has Myriad Genetics performed over the past 5 years?

-20.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: MYGN's earnings have declined by -20.9% per year over the past 5 years.

Accelerating Growth: MYGN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: MYGN had negative earnings growth (-96.5%) over the past year, making it difficult to compare to the Biotechs industry average (78.4%).


Return on Equity

High ROE: MYGN's Return on Equity (0.4%) is considered low.


Return on Assets

ROA vs Industry: MYGN's Return on Assets is below or equal to the Biotechs industry average last year.


Return on Capital Employed

ROCE Improving: MYGN's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Myriad Genetics's financial position?


Financial Position Analysis

Short Term Liabilities: MYGN's short term assets ($348.6M) exceeds its short term liabilities ($117.8M)

Long Term Liabilities: MYGN's short term assets (348.6M) do not cover its long term liabilities (356.0M)


Debt to Equity History and Analysis

Debt Level: MYGN's debt to equity ratio (21.4%) is considered satisfactory

Reducing Debt: Insufficient data to determine if MYGN's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: MYGN's debt is well covered by operating cash flow (35.8%).

Interest Coverage: MYGN's interest payments on its debt are well covered by EBIT (3.4x coverage).


Balance Sheet

Inventory Level: MYGN has a low level of unsold assets or inventory.

Debt Coverage by Assets: MYGN's debt is covered by short term assets (assets are 1.492930x debt).


Next Steps

Dividend

What is Myriad Genetics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate MYGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MYGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if MYGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MYGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MYGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Myriad Genetics's salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average management tenure


CEO

Mark Capone (57yo)

4.3yrs

Tenure

US$7,054,950

Compensation

Mr. Mark Christopher Capone has been the Chief Executive Officer and President at Myriad Genetics Inc. since July 1, 2015. Mr. Capone served as the President of Myriad Genetic Laboratories at Myriad Geneti ...


CEO Compensation Analysis

Compensation vs. Market: Mark's total compensation ($USD7.05M) is about average for companies of similar size in the US market ($USD4.08M).

Compensation vs Earnings: Mark's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Management Age and Tenure

4.3yrs

Average Tenure

54.5yo

Average Age

Experienced Management: MYGN's management team is considered experienced (4.3 years average tenure).


Board Age and Tenure

9.7yrs

Average Tenure

67yo

Average Age

Experienced Board: MYGN's board of directors are considered experienced (9.7 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$61,22512 Mar 19
Ralph McDade
EntityIndividual
Shares1,975
Max PriceUS$31.00

Ownership Breakdown


Management Team

  • Gary King (63yo)

    Executive Vice President of International Operations

    • Tenure: 9.3yrs
  • Jerry Lanchbury (60yo)

    Chief Scientific Officer

    • Tenure: 9.7yrs
    • Compensation: US$2.38m
  • Rishi Kacker

    Chief Technology Officer

    • Tenure: 1.3yrs
  • Scott Gleason

    Vice President of Investor Relations

    • Tenure: 0yrs
  • Mark Capone (57yo)

    CEO, President & Director

    • Tenure: 4.3yrs
    • Compensation: US$7.05m
  • Ron Rogers (51yo)

    Executive Vice President of Corporate Communications

    • Tenure: 0yrs
  • R. Riggsbee (48yo)

    Executive VP

    • Tenure: 5yrs
    • Compensation: US$2.65m
  • Alec Ford (52yo)

    President of Myriad Women’s Health

    • Tenure: 4.3yrs
    • Compensation: US$2.76m
  • Ben Jackson

    Executive VP

    • Tenure: 0.3yrs
  • Clivetty Martinez

    Chief Compliance Officer

    • Tenure: 0.8yrs

Board Members

  • Larry Best (70yo)

    Director

    • Tenure: 10.1yrs
    • Compensation: US$330.49k
  • Wally Gilbert (87yo)

    Vice Chairman

    • Tenure: 0yrs
    • Compensation: US$319.99k
  • John Henderson (75yo)

    Chairman

    • Tenure: 14.5yrs
    • Compensation: US$432.49k
  • Dennis Langer (67yo)

    Director

    • Tenure: 15.4yrs
    • Compensation: US$340.49k
  • Lee Newcomer (67yo)

    Director

    • Tenure: 0.08yrs
  • Colleen Reitan (60yo)

    Director

    • Tenure: 0.08yrs
  • Heiner Dreismann (66yo)

    Director

    • Tenure: 9.3yrs
    • Compensation: US$334.99k
  • Mark Capone (57yo)

    CEO, President & Director

    • Tenure: 4.3yrs
    • Compensation: US$7.05m
  • S. Phanstiel (61yo)

    Director

    • Tenure: 10.1yrs
    • Compensation: US$347.49k

Company Information

Myriad Genetics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Myriad Genetics, Inc.
  • Ticker: MYGN
  • Exchange: NasdaqGS
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.180b
  • Shares outstanding: 73.87m
  • Website: https://myriad.com

Number of Employees


Location

  • Myriad Genetics, Inc.
  • 320 Wakara Way
  • Salt Lake City
  • Utah
  • 84108
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MYGNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 1995
MYDDB (Deutsche Boerse AG)YesCommon StockDEEUROct 1995
0K3WLSE (London Stock Exchange)YesCommon StockGBUSDOct 1995

Biography

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide. The company offers myRisk Hereditary Cancer, a DNA sequencing  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 01:30
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)